Real-world management and patient perspectives on QOL with neuroendocrine tumours: An ANZ perspective

On 2 September 2020 a webinar was held titled “NET 2020” for Health Professionals and was sponsored by Novartis.

There were around 120 attendees at the event from across Australia which had a panel of NET Specialists providing information about current treatment options, an opportunity to take part in an in-depth discussion of a functional GEPNET patient case, a debate on the optimal clinical approach for non-functional GEPNET, and new data on quality of life issues affecting NET patients to improve supportive care. This article provides a summary of the presentations at the event which will be extremely interesting to the medical community.

Click the button below for full article.


Download here

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

ANZSNM 56th Annual Conference – Canberra (ACT), Australia

Nurses Workshop, Sunday, 17 May 2026

NECA Canberra NET Patient Forum, Saturday, 16 May 2026

NECA Joins Boehringer Ingelheim Panel Discussion on Clinical Trials and Patient Access

Tax Appeal

Screenshot 2026-05-20 at 2.12.07 PM

Help 31,000+ neuroendocrine cancer patients get the specialised care they deserve.

Every dollar raised is fully tax deductible and helps fund much needed advocacy efforts and patient support.